Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity

Obesity medications may be part of a comprehensive care plan for adults with obesity. The Obesity Association, a division of the American Diabetes Association (ADA), developed comprehensive, evidence-based guidelines on the pharmacologic treatment of obesity in adults. When used in conjunction with lifestyle modifications, obesity medications have demonstrated efficacy in inducing and sustaining weight reduction while concurrently improving clinical outcomes of obesity and obesity-related diseases and complications. Healthcare professionals should engage people with obesity in a person-centered, shared decision-making approach when selecting an obesity medication to optimize health outcomes while emphasizing individual needs and preferences. The ADA’s Obesity Association encourages healthcare professionals to adopt these guidelines for treatment of obesity in adults.

• Publication year

  2025

• Venue

  BMJ Open Diabetes Research & Care

• Publication date

  2025-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bmjdrc-2025-005729PMID 41529914PMCID 12815056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes

  2025cited by this paper
• Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database

  2025cited by this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

  2025cited by this paper
• Definition and diagnostic criteria of clinical obesity.

  2025cited by this paper
• Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study

  2025cited by this paper
• 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.

  2025cited by this paper
• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?

  2025cited by this paper
• Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials

  2025cited by this paper
• Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists

  2025cited by this paper
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

  2025cited by this paper
• Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial

  2025cited by this paper
• Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial

  2025cited by this paper
• Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

  2025cited by this paper
• Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.

  2025cited by this paper
• Longitudinal Analysis of Obesity Drug Use and Public Awareness

  2025cited by this paper
• Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

  2025cited by this paper
• Implications of the European Association for the Study of Obesity's New Framework Definition of Obesity: Prevalence and Association With All-Cause Mortality.

  2025cited by this paper
• Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors

  2025cited by this paper
• Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system

  2025cited by this paper
• Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

  2025cited by this paper
• Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system

  2025cited by this paper
• Introduction and methodology: Standards of Care in Overweight and Obesity—2025

  2025cited by this paper
• Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study

  2025cited by this paper
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight

  2025cited by this paper
• A Primary Care–Based Weight Navigation Program

  2024cited by this paper
• Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

  2024cited by this paper
• Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years

  2024cited by this paper
• Shared Decision-Making in Cardiovascular Risk Factor Management

  2024cited by this paper
• Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial

  2024cited by this paper
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

  2024cited by this paper
• Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

  2024cited by this paper
• Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.

  2024cited by this paper
• G LP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials

  2024cited by this paper
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

  2024cited by this paper
• Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial

  2024cited by this paper
• Switching to tirzepatide 5 mg from GLP-1 RAs: Clinical expectations in the first 12 weeks of treatment.

  2024cited by this paper
• Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes.

  2024influential reference
• The impact of approved anti-obesity medications on osteoarthritis

  2024cited by this paper
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

  2024cited by this paper
• Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.

  2024cited by this paper
• Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

  2024influential reference
• Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

  2024cited by this paper
• Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

  2024cited by this paper
• Nutritional considerations with antiobesity medications

  2024cited by this paper
• Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series

  2024cited by this paper
• Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial

  2024cited by this paper
• Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association.

  2024cited by this paper
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs

  2024cited by this paper
• Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

  2024cited by this paper
• An obesity medicine curriculum increases the obesity care self‐efficacy of internal medicine residents in the primary care setting

  2024cited by this paper
• Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment

  2024cited by this paper
• Semaglutide and blood pressure: an individual patient data meta-analysis

  2024cited by this paper
• Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials

  2024cited by this paper
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

  2024cited by this paper
• Adoption of telemedicine for obesity treatment during the COVID-19 pandemic achieved comparable outcomes to in-person visits

  2024cited by this paper
• Tirzepatide for Obesity Treatment and Diabetes Prevention.

  2024influential reference
• The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression

  2024cited by this paper
• Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

  2024cited by this paper
• Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

  2024cited by this paper
• Sudden Death in Obesity: Mechanisms and Management.

  2024cited by this paper
• Do Personalized Nutrition Interventions Improve Dietary Intake and Risk Factors in Adults With Elevated Cardiovascular Disease Risk Factors? A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2024cited by this paper
• Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.

  2024influential reference
• Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial

  2024cited by this paper
• Duties, tasks, knowledge and skills of an obesity medicine physician: A practice analysis

  2024cited by this paper
• Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases

  2024cited by this paper
• Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

  2024cited by this paper
• Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.

  2024cited by this paper
• Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature

  2024cited by this paper
• Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis

  2024influential reference
• Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.

  2024cited by this paper
• Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: A systematic review and meta-analysis.

  2024cited by this paper
• Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

  2024cited by this paper
• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

  2024cited by this paper
• The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

  2024cited by this paper
• Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years.

  2024cited by this paper
• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

  2024influential reference
• Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

  2024cited by this paper
• Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity

  2024cited by this paper
• Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication

  2024cited by this paper
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

  2024influential reference
• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

  2024cited by this paper
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

  2023cited by this paper
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

  2023cited by this paper
• Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

  2023cited by this paper
• Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis

  2023cited by this paper
• Hormonal Gut–Brain Signaling for the Treatment of Obesity

  2023cited by this paper
• The Impact of Tirzepatide and Glucagon-like Peptide 1 Receptor Agonists on Oral Hormonal Contraception.

  2023influential reference
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

  2023cited by this paper
• Five-year weight loss maintenance with obesity pharmacotherapy.

  2023cited by this paper
• Use and continuity of weight‐modifying medications among adults with diabetes and overweight/obesity: US population study

  2023cited by this paper
• Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence

  2023cited by this paper
• The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials

  2023cited by this paper
• Use of medications associated with weight change among participants in the All of Us research programme

  2023cited by this paper
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

  2023cited by this paper
• Dose–response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials

  2023cited by this paper
• Real-World Effect of a Potential Drug-Drug Interaction Between Topiramate and Oral Contraceptives on Unintended Pregnancy Outcomes.

  2023cited by this paper
• Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.

  2023cited by this paper
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

  2023cited by this paper
• Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program

  2023cited by this paper
• Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review

  2023cited by this paper

• Medikamentöse Therapie der Adipositas

  2026cites this paper